Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SB756050 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | 15 mg SB756050 or placebo |
| Cohort 2 | EXPERIMENTAL | Planned dose for Cohorts 2 50mg SB756050 or placebo |
| Cohort 3 | EXPERIMENTAL | Planned dose for Cohort 3 150mg SB756050 or placebo |
| Cohort 4 | EXPERIMENTAL | Planned dose for Cohort 4 600mg SB756050 or placebo |
| Name | Type | Description |
|---|---|---|
| SB756050 | DRUG | doses are planned to be 15mg to 600mg doses may be altered based on plasma concentrations |
Inclusion Criteria: * Male or female subjects, 18 - 60 years of age, inclusive, at the time of signing the informed consent * A female subject is eligible to participate if she is of non-childbearing potential, defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or p...
SB756050 is an investigational small molecule being studied for the treatment of Type 2 Diabetes Mellitus. It is in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is intended to affect subjects with Type 2 diabetes, as evaluated in a completed clinical trial.
SB756050 is being developed by GSK plc, a global pharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting clinical research on this investigational drug for Type 2 Diabetes Mellitus.
SB756050 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved for commercial use. The Phase 1 trial has been completed, and the drug is no longer in active clinical testing according to available data.
SB756050 has one completed clinical trial registered under NCT00733577, titled "A Study to Test How SB756050 Affects Subjects With Type 2 Diabetes Mellitus After 6 Days of Dosing." This Phase 1 study enrolled 48 participants in the United States and was a controlled, randomized trial.
No alternative names for SB756050 have been identified. The drug is known by its code name SB756050 and is being developed by GSK plc for Type 2 Diabetes Mellitus. It is a small molecule in Phase 1 clinical development.